arginyl-tryptophyl-N-methylphenylalanyl-tryptophyl-leucyl-methioninamide: an anticancer peptide; a broad spectrum neuropeptide growth factor antagonist; RN given refers to (D-Trp,D-Trp)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 163960 |
| CHEMBL ID | 4303227 |
| MeSH ID | M0251663 |
| Synonym |
|---|
| arginyl-tryptophyl-n-methylphenylalanyl-tryptophyl-leucyl-methioninamide |
| arg-trp-n-methyl-phe-trp-leu-met-nh2 |
| rw-n(me)f-wlm-nh2 |
| l-methioninamide, l-arginyl-o-tryptophyl-n-methyl-l-phenylalanyl-d-tryptophyl-l-leucyl- |
| l-arginyl-o-tryptophyl-n-methyl-l-phenylalanyl-d-tryptophyl-l-leucyl-l-methioninamide |
| h-arg-d-trp-n(me)phe-d-trp-leu-met-nh2 |
| antagonist g |
| 115150-59-9 |
| (2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-(1h-indol-3-yl)propanoyl]-methylamino]-3-phenylpropanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-n-[(2s)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]-4-methylpent |
| [arg6,d-trp7,9,n-mephe8]-substance p(6-11) |
| AKOS024456877 |
| HY-P1185 |
| CS-0028917 |
| an-tagonist g |
| (arg6,d-trp7?9,n-me-phe8)-substance p (6-11) |
| mfcd00133831 |
| (s)-n-((5s,8s,11r,14s,17r)-11-((1h-indol-3-yl)methyl)-14-benzyl-5-carbamoyl-18-(1h-indol-3-yl)-8-isobutyl-15-methyl-7,10,13,16-tetraoxo-2-thia-6,9,12,15-tetraazaoctadecan-17-yl)-2-amino-5-guanidinopentanamide |
| l-methioninamide, l-arginyl-d-tryptophyl-n-methyl-l-phenylalanyl-d-tryptophyl-l-leucyl- |
| CHEMBL4303227 |
| arg-d-trp-n-me-phe-d-trp-leu-met-nh2 |
| MS-31778 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Because neuropeptides are part of complex neurohumoral pathways, we have sought to develop novel pharmacodynamic approaches as part of the early clinical development of this potential anticancer drug." | ( Forearm blood flow and local responses to peptide vasodilators: a novel pharmacodynamic measure in the phase I trial of antagonist G, a neuropeptide growth factor antagonist. Byrne, B; Clive, S; Jodrell, DI; MacLellan, A; Robson, L; Smyth, JF; Webb, DJ; Young, A, 2001) | 0.31 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (53.85) | 18.2507 |
| 2000's | 5 (38.46) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.54) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (7.69%) | 5.53% |
| Reviews | 1 (7.69%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (84.62%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||